Core Viewpoint - Zai Ding Pharma reported a total revenue of $110 million for Q2 2025, reflecting a 9% year-over-year increase, and reaffirmed its full-year revenue guidance of $560 million to $590 million [1] Financial Performance - The operating loss for Q2 2025 was $54.9 million, a 28% year-over-year reduction, while the adjusted operating loss narrowed by 37% to $34.2 million [1] - The company is on track to achieve profitability by Q4 2025, supported by a solid cash reserve and growing commercialization efforts [3] Product Development and Pipeline - The usage of Efgartigimod reached record levels, bolstered by updated treatment guidelines for myasthenia gravis in China [1][3] - ZL-1310 (DLL3 ADC) demonstrated an objective response rate (ORR) of 67% across all dosage groups in a study for second-line extensive-stage small cell lung cancer, with a 79% ORR in the 1.6 mg/kg group [1] - The company plans to initiate a registrational clinical study for ZL-1310 in H2 2025 and is preparing for the global Phase 3 FORTITUDE-101 study of Bemarituzumab for FGFR2b overexpressing gastric cancer [1][2] Strategic Vision - The CEO emphasized that Zai Ding Pharma is entering a critical development phase focused on innovation, scalability, and efficient execution, with substantial progress across all business areas [2] - The company is preparing for the launch of multiple key products, including KarXT and Bemarituzumab, which are expected to drive the next growth phase alongside Efgartigimod and other multi-indication products [3]
再鼎医药(09688.HK)第二季度调整后经营亏损收窄37% 正稳步迈向第四季度实现盈利的目标